临床前药理毒理研究专员/助理

Chinese biopharmaceutical company established in September 2013 as a subsidiary of the listed Zhejiang Huahai Pharmaceutical, traded in Shanghai under code 600521, with three hundred million yuan of registered capital and cumulative investment of seven hundred million yuan, recognised as a national high-tech enterprise. Has built an integrated biologic drug discovery platform and system covering monoclonal antibodies, bispecific antibodies, fusion proteins and antibody drug conjugates together with GMP compliant drug substance and drug product pilot facilities. Concentrates on oncology, autoimmune disease and ophthalmology with more than twenty programmes in development, several of which have reached clinical study with trials running in the United States, New Zealand and China.